Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    -4.00 (-0.18%)
Bid:
2,192.00
Ask:
2,220.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

AGM and Interim Management Statement

8 Nov 2012 07:00

RNS Number : 6077Q
Genus PLC
08 November 2012
Ā 



For immediate release

8 November 2012

Ā 

Ā 

Genus plc

('Genus' or 'the Company')

Annual General Meeting ('AGM') and Interim Management Statement

Ā 

At the AGM of Genus to be held at 11.00am today, the following interim management statement will be made for the trading period from 1 July to 31 October 2012.

Ā 

Current Trading

Following last year's record results, revenues for the four months to 31 October 2012 were slightly ahead of the strong performance achieved in the same period last year. Operating profits were lower than the same period last year driven by higher feed costs in our genetic nucleus farms and by delayed sales in Genus ABS caused by adverse weather conditions in Latin America.

Ā 

The overall results have benefited from solid performances in Genus PIC and Genus Asia. In addition the strength of the Genus business model has limited the financial effect on Genus of the higher feed costs that are affecting many of our customers.

Ā 

Genus PIC, comprising the porcine operations in North America, Latin America and Europe, achieved continued volume growth across all three regions. Operating profits were at a similar level to last year despite higher feed costs in our nucleus farm operations and planned increased investment in product development. Performance has benefited from continued growth in the CBV Plus and CBV Max programmes in North America and volume growth in Latin America. Europe has performed ahead of last year reflecting the start of restructuring benefits and the strengthening European porcine market.

Ā 

Genus ABS, comprising the dairy and AI beef businesses in North America, Latin America and Europe, had a slow start to the year. Volumes were lower in Latin America where adverse weather conditions in Argentina and Brazil have caused a delay in semen sales. We expect these sales to be recovered as the year progresses. Performance in North America and Europe was slightly ahead of last year.

Ā 

Genus Asia has had a good start to the year. Revenues and profits were in line with the strong performance achieved in the same period last year.

Ā 

As expected finance costs were higher than last year, reflecting the previously indicated increase in pension interest costs following the additional pension provision made at 30 June 2012.

Ā 

Financial Position

Net debt at the end of October 2012 was at a similar level to end June 2012 and well below the same time last year.

Ā 

Strategy

We have made a good start in implementing our strategy to accelerate the rate of profit growth from 2014 onwards.

Ā 

Following the implementation of a new market-place oriented organisation structure in July 2012, we are establishing global technical services, global marketing and a global supply chain for each of our porcine and dairy/AI beef businesses. This is already starting to create opportunities to enhance customer service which is a key element of our overall growth strategy.

Ā 

In line with our strategy, we have appointed Saskia Korink Romani to the new position of Chief Marketing Officer. Saskia, who joins in January 2013, brings significant international business and marketing experience having worked for 10 years at Cargill, most recently as Vice President of Marketing, Animal Nutrition Division.

Ā 

In Asia, key personnel appointments have been made as part of our plans to ensure we have the right resources in place to meet our growth aspirations.

Ā 

In China, the initial stocking of the Besun porcine joint venture farm has been completed as planned and discussions with other potential joint venture partners are progressing.

Ā 

Outlook

We expect to see a gradual improvement in performance as the year progresses particularly after the slow start in our Genus ABS business. We believe Genus remains on course to achieve another year of growth.

Ā 

With the investments being made in the current year, particularly in emerging markets such as China and in core competencies such as marketing, technical services and product development, the Group is well placed to take advantage of the long-term opportunities available in the global animal genetics market.

Ā 

Ā 

For further information please contact:-

Ā 

Genus plc: Tel: 01256 345970

Karim Bitar, Chief Executive

John Worby, Finance Director

Ā 

Ā 

Buchanan: Tel: 0207 466 5000

Charles Ryland

Ā 

This announcement is available on the Genus website, www.genusplc.com

Ā 

Ā 

About Genus

Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across all livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Ā 

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Genus' customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chain.

Ā 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

Ā 

With headquarters in Basingstoke, United Kingdom, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Ā 

Ā 

Ā 

This information is provided by RNS
The company news service from the London Stock Exchange
Ā 
END
Ā 
Ā 
MSCUBUURURAARUA
Date   Source Headline
26th Feb 20257:00 amRNSNon-Executive Director Retirement
3rd Feb 20253:17 pmRNSBlock Listing Six Monthly Return
3rd Feb 20259:40 amRNSTotal Voting Rights
15th Jan 20257:00 amRNSHalf Year Trading Update – Ahead of expectations
12th Dec 20245:07 pmRNSNotification of Major Holdings
20th Nov 20243:32 pmRNSResults of AGM
20th Nov 20247:00 amRNSAGM Trading Update
1st Nov 202410:42 amRNSTotal Voting Rights
22nd Oct 20247:00 amRNSChief Financial Officer Retirement
14th Oct 20247:00 amRNSAnnual Report and Annual General Meeting
18th Sep 202411:17 amRNSDirector/PDMR Shareholding
16th Sep 20244:29 pmRNSDirector/PDMR Shareholding
12th Sep 20244:51 pmRNSDirector/PDMR Shareholding
12th Sep 20247:00 amRNSDirector/PDMR Shareholding
9th Sep 20247:00 amRNSDirector/PDMR Shareholding
6th Sep 202412:31 pmRNSDirector/PDMR Shareholding
6th Sep 202412:30 pmRNSDirector/PDMR Shareholding
5th Sep 20247:00 amRNSPreliminary Results
1st Aug 20244:26 pmRNSBlock Listing Six Monthly Return
1st Aug 20243:38 pmRNSTotal Voting Rights
17th Jul 20247:00 amRNSTrading Update
3rd Jun 202410:48 amRNSHolding(s) in Company
1st May 20241:59 pmRNSTotal Voting Rights
22nd Feb 20247:00 amRNSInterim Results
15th Feb 20247:00 amRNSTrading Update
1st Feb 20244:24 pmRNSBlock listing Interim Review
1st Feb 20244:21 pmRNSTotal Voting Rights
12th Dec 20237:00 amRNSNon-Executive Director Appointment
22nd Nov 20231:08 pmRNSResult of AGM
22nd Nov 20237:00 amRNSAGM Trading Update
1st Nov 20234:46 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSCapital Markets Event
13th Oct 20237:00 amRNSAnnual Report and Annual General Meeting
5th Oct 202310:19 amRNSPos. determination-PRRS resistant pigs-Colombia
2nd Oct 202311:12 amRNSTotal Voting Rights
15th Sep 20231:07 pmRNSDirector/PDMR Shareholding
15th Sep 202310:04 amRNSDirector/PDMR Shareholding
7th Sep 20237:00 amRNSPreliminary Results
25th Aug 20238:35 amRNSNotification of Major Holdings
23rd Aug 20239:25 amRNSDirectorate Change
1st Aug 202311:41 amRNSBlock listing Interim Review
1st Aug 202311:36 amRNSTotal Voting Rights
3rd Jul 202311:02 amRNSTotal Voting Rights
16th Jun 20235:33 pmRNSNational Milk Records plc - Form 8.3
16th Jun 20235:10 pmRNSForm 8.3 (OPD) - National Milk Records plc
8th Jun 20233:51 pmRNSDirector/PDMR Shareholding
7th Jun 20235:11 pmRNSNotification of Major Holdings
7th Jun 20235:08 pmRNSNotification of Major Holdings
5th Jun 20239:12 amRNSAdditional Listing
24th May 20234:54 pmRNSNotification of Major Holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.